Transgene (NASDAQ:TNGX) Advances TG4050 Development Through NEC Bio Partnership

April 2, 2026

Market Overview The biotechnology sector showed notable activity as Transgene (NASDAQ:TNGX) pushed forward on its immuno-oncology front. Shares of Transgene have attracted investor attention amidst ongoing developments related to their TG4050 therapeutic candidate, aimed at treating head and neck cancers. The stock movement reflects cautious optimism driven by pipeline progress and strategic collaborations in the immunotherapy space. As the immuno-oncology domain remains competitive and highly scrutinized, Transgene (NASDAQ:TNGX) continues to…

Read More >>